SBC Medical Group Holdings Inc. (NASDAQ: SBC), the Japanese owner and operator of a chain of aesthetic medical clinics, has completed a strategic investment in OrangeTwist, a U.S.-based medspa chain, signaling its official foray into the U.S. market. The partnership, announced late last month, aims to combine SBC's operational expertise with OrangeTwist's advanced management system to capture a share of the growing medical aesthetics industry, which SBC estimates will expand from $34 billion today to $48 billion by 2030.
OrangeTwist, which operates 24 locations across six U.S. states, specializes in non-invasive aesthetic treatments such as injectables, fillers, laser treatments and body contouring. These services are in high demand among U.S. consumers, driven by an aging population and a preference for treatments with minimal risk and downtime. Through the partnership, SBC will provide funding and professional know-how to help OrangeTwist enhance its offerings, open new locations more quickly, and address "white space" markets—cities with high demand but few competitors. This first-mover advantage could be pivotal as SBC seeks to establish a strong foothold in the U.S.
Stephen Rodgers, global head of planning and strategy at SBC Medical, told Benzinga that the company plans to make more strategic investments in the U.S., focusing on local partnerships rather than replicating its Japanese model. "As part of SBC’s global expansion, we are working hard to find local partnerships rather than copying and pasting what we did in Japan," Rodgers said in an interview. SBC looks for partners that align with its mission, are market leaders and can scale, similar to OrangeTwist. Beyond joint operations, the two companies plan to co-develop branded products and sell existing products in each other's spas.
The investment also positions SBC to capitalize on the broader longevity industry, which is shifting from increasing lifespan to boosting "healthspan" through personalized, preventative and tech-driven solutions. According to Gabelli Research, the global anti-aging market is expected to surpass $120 billion by 2030, growing at a CAGR of 7% from 2025-2030. North America accounts for approximately 30% of this market, with robust growth also coming from Asia. SBC believes its existing infrastructure and track record in aesthetics and wellness services make it well-suited to offer longevity-related services such as AI-powered diagnostics, GLP-1 weight-loss drugs and regenerative therapies.
While OrangeTwist provides a U.S. foothold, SBC is also expanding in Japan and Southeast Asia. The company is using its proven business model to help Asian clinics with one-stop management, including staff training, better pricing for medical equipment and management services. Its global expansion strategy rests on three core tenets: partnering with high-performing regional operators with scalable business models, deploying expertise to drive efficiencies, and securing first-mover advantages. Non-invasive cosmetic treatments are ideally suited for Asian markets, where consumers prefer natural-looking treatments with short recovery times. By standardizing services, SBC ensures consistent quality and pricing across its network in Japan, Thailand and Singapore.
SBC Medical's partnership model, which emphasizes local collaboration and operational synergy, is designed to be replicated across different countries. By sharing its successful approach with local providers, the company aims to create a single, trusted global brand for aesthetic beauty services. The investment in OrangeTwist, supported by institutional shareholders Hildred Capital and Athyrium Capital, is just the beginning of SBC's U.S. expansion. As the company pursues its quest to become a leading provider of aesthetic services worldwide, its focus on strategic partnerships and market-specific strategies could drive significant growth in the coming years.
For more information on SBC Medical, visit Benzinga for the full interview with Stephen Rodgers and additional disclosures.
